Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO?

Open Access

Peer-reviewed

Research Article

Stella Benbaba,

Affiliation Médecins Sans Frontières, Mumbai, India
⨯
Petros Isaakidis ,

* E-mail: msfocb-asia-epidemio@brussels.msf.org

Affiliations Médecins Sans Frontières, Mumbai, India, Médecins Sans Frontières, Operational Research Unit, Luxembourg City, Luxembourg
⨯
Mrinalini Das,

Affiliation Médecins Sans Frontières, Mumbai, India
⨯
Sonakshi Jadhav,

Affiliation Médecins Sans Frontières, Mumbai, India
⨯
Tony Reid,

Affiliation Médecins Sans Frontières, Operational Research Unit, Luxembourg City, Luxembourg
⨯
Jennifer Furin

Affiliation Tuberculosis Research Unit, Case Western Reserve University, Cleveland, Ohio, United States of America
⨯

Reader Comments (0)

HIV
Is the Subject Area "HIV" applicable to this article?

Thanks for your feedback.
Physicians
Is the Subject Area "Physicians" applicable to this article?

Thanks for your feedback.
Patients
Is the Subject Area "Patients" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Tuberculosis
Is the Subject Area "Tuberculosis" applicable to this article?

Thanks for your feedback.
Nurses
Is the Subject Area "Nurses" applicable to this article?

Thanks for your feedback.
Antiretroviral therapy
Is the Subject Area "Antiretroviral therapy" applicable to this article?

Thanks for your feedback.